Top

Journal of Autism and Developmental Disorders

Gepubliceerd in:

24-11-2022 | Original Paper

Efficacy of Sulforaphane in Treatment of Children with Autism Spectrum Disorder: A Randomized Double-Blind Placebo-Controlled Multi-center Trial

Auteurs: Jianjun Ou, Robert C. Smith, Russell H. Tobe, Jingjing Lin, Jen Arriaza, Jed W. Fahey, Ruiting Liu, Ying Zeng, Yanan Liu, Lian Huang, Yidong Shen, Yamin Li, Daomeng Cheng, Brian Cornblatt, John M. Davis, Jingping Zhao, Renrong Wu, Hua Jin

Gepubliceerd in: Journal of Autism and Developmental Disorders | Uitgave 2/2024

Abstract

Sulforaphane has been reported to possibly improve core symptoms associated with autism spectrum disorders from mostly small size studies. Here we present results of a larger randomized clinical trial (N = 108) in China. There were no significant changes in caregiver rated scales between sulforaphane and placebo groups. However, clinician rated scales showed a significant improvement in the sulforaphane group, and one third of participants showed at least a 30% decrease in score by 12 weeks treatment. The effects of sulforaphane were seen across the full range of intelligence and greater in participants over 10 years. Sulforaphane was safe and well-tolerated even for young children. The inconsistent results between caregiver and clinician rated scales suggest more clinical trials are needed to confirm our findings.

vorige artikel Autism Spectrum Disorder and Anxiety Among Transgender Youth: Use of the Social Communication Questionnaire (SCQ)

volgende artikel “Neural Noise” in Auditory Responses in Young Autistic and Neurotypical Children

Alleen toegankelijk voor geautoriseerde gebruikers

Achenbach, T. M., & Rescorla, L. A. (2000). Manual for the ASEBA preschool forms & profiles. VT University of Vermont, Research Center for Children, Youth, & Families.

Achenbach, T. M., & Rescorla, L. A. (2001). Manual for the ASEBA School-Age Forms & Profiles. VT University of Vermont, Research Center for Children, Youth, & Families.

Anagnostou, E., Jones, N., Huerta, M., Halladay, A. K., Wang, P., Scahill, L., Horrigan, J. P., Kasari, C., Lord, C., Choi, D., Sullivan, K., & Dawson, G. (2015). Measuring social communication behaviors as a treatment endpoint in individuals with autism spectrum disorder. Autism, 19, 622–636. https://doi.org/10.1177/1362361314542955CrossRefPubMed

Benjamini, Y., & Hochberg, Y. (1995). Controlling the false discovery rate: A practical and powerful approach to multiple testing. Journal of the Royal Statistical Society Series B: Methodological, 57, 289–300.

Bent, S., Lawton, B., Warren, T., Widjaja, F., Dang, K., Fahey, J. W., Cornblatt, B., Kinchen, J. M., Delucchi, K., & Hendren, R. L. (2018). Identification of urinary metabolites that correlate with clinical improvements in children with autism treated with sulforaphane from broccoli. Molecular Autism, 9, 35. https://doi.org/10.1186/s13229-018-0218-4CrossRefPubMedPubMedCentral

Bosshard, M., Aprigliano, R., Gattiker, C., Palibrk, V., Markkanen, E., Backe, P. H., Pellegrino, S., Raymond, F. L., Froyen, G., Altmeyer, M., Bjørås, M., Dianov, G. L., & van Loon, B. (2017). Impaired oxidative stress response characterizes HUWE1-promoted X-linked intellectual disability. Scientific Reports, 7, 15050. https://doi.org/10.1038/s41598-017-15380-yCrossRefPubMedPubMedCentral

Choque Olsson, N., & Bolte, S. (2014). Brief report: “Quick and (not so) dirty” assessment of change in autism: Cross-cultural reliability of the developmental disabilities CGAS and the OSU autism CGI. Journal of Autism and Developmental Disorders, 44, 1773–1778. https://doi.org/10.1007/s10803-013-2029-yCrossRefPubMed

Constantino, J. N., Davis, S. A., Todd, R. D., Schindler, M. K., Gross, M. M., Brophy, S. L., Metzger, L. M., Shoushtari, C. S., Splinter, R., & Reich, W. (2003). Validation of a brief quantitative measure of autistic traits: Comparison of the social responsiveness scale with the autism diagnostic interview-revised. Journal of Autism and Developmental Disorders, 33, 427–433. https://doi.org/10.1023/a:1025014929212CrossRefPubMed

Dunn, L. M., & Dunn, D. M. (2007). Peabody picture vocabulary test (4th ed.). London.

Fahey, J. W., Wade, K. L., Stephenson, K. K., Panjwani, A. A., Liu, H., Cornblatt, G., Cornblatt, B. S., Ownby, S. L., Fuchs, E., Holtzclaw, W. D., & Cheskin, L. J. (2019). Bioavailability of sulforaphane following ingestion of glucoraphanin-rich broccoli sprout and seed extracts with active myrosinase: A pilot study of the effects of proton pump inhibitor administration. Nutrients, 11, 1489. https://doi.org/10.3390/nu11071489CrossRefPubMedPubMedCentral

Guerrero-Beltran, C. E., Calderon-Oliver, M., Pedraza-Chaverri, J., & Chirino, Y. I. (2012). Protective effect of sulforaphane against oxidative stress: Recent advances. Experimental & Toxicologic Pathology, 64, 503–508. https://doi.org/10.1016/j.etp.2010.11.005CrossRef

Harrison, P., & Oakland, T. (2008). Adaptive behavior assessment system-II. Western Psychological Services.

Hollander, E., Jacob, S., Jou, R., McNamara, N., Sikich, L., Tobe, R., Smith, J., Sanders, K., Squassante, L., Murtagh, L., Gleissl, T., Wandel, C., & Veenstra-VanderWeele, J. (2022). Balovaptan vs Placebo for social communication in childhood autism spectrum disorder: A randomized clinical trial. JAMA Psychiatry. https://doi.org/10.1001/jamapsychiatry.2022.1717CrossRefPubMedPubMedCentral

Hsueh, H. M., Chen, J. J., & Kodell, R. L. (2003). Comparison of methods for estimating the number of true null hypotheses in multiplicity testing. Journal of Biopharmaceutical Statistics, 13, 675–689. https://doi.org/10.1081/bip-120024202CrossRefPubMed

Jin, Z. J., Yang, Y., Liu, S. J., Huang, H., & Jin, X. M. (2018). Prevalence of DSM-5 autism spectrum disorder among school-based children aged 3–12 years in Shanghai, China. Journal of Autism and Developmental Disorders, 48, 2434–2443. https://doi.org/10.1007/s10803-018-3507-zCrossRefPubMed

Krasileva, K. E., Sanders, S. J., & Bal, V. H. (2017). Peabody picture vocabulary test: Proxy for verbal IQ in genetic studies of autism spectrum disorder. Journal of Autism and Developmental Disorders, 47, 1073–1085. https://doi.org/10.1007/s10803-017-3030-7CrossRefPubMed

Lam, K. S., & Aman, M. G. (2007). The repetitive behavior scale-revised: Independent validation in individuals with autism spectrum disorders. Journal of Autism and Developmental Disorders, 37, 855–866. https://doi.org/10.1007/s10803-006-0213-zCrossRefPubMed

Levine, J., & Schooler, N. R. (1992). General versus specific inquiry with SAFTEE. Journal of Clinical Psychopharmacology, 12, 448. https://doi.org/10.1097/00004714-199212000-00017CrossRefPubMed

Levy, S. E., Mandell, D. S., Merhar, S., Ittenbach, R. F., & Pinto-Martin, J. A. (2003). Use of complementary and alternative medicine among children recently diagnosed with autistic spectrum disorder. Journal of Developmental & Behavioral Pediatrics, 24, 418–423. https://doi.org/10.1097/00004703-200312000-00003CrossRef

Liu, H., Zimmerman, A. W., Singh, K., Connors, S. L., Diggins, E., Stephenson, K. K., Dinkova-Kostova, A. T., & Fahey, J. W. (2020). Biomarker exploration in human peripheral blood mononuclear cells for monitoring sulforaphane treatment responses in autism spectrum disorder. Scientific Reports. https://doi.org/10.1038/s41598-020-62714-4CrossRefPubMedPubMedCentral

Lord, C., Elsabbagh, M., Baird, G., & Veenstra-Vanderweele, J. (2018). Autism spectrum disorder. Lancet, 392, 508–520. https://doi.org/10.1016/s0140-6736(18)31129-2CrossRefPubMedPubMedCentral

Lynch, R., Diggins, E. L., Connors, S. L., Zimmerman, A. W., Singh, K., Liu, H., Talalay, P., & Fahey, J. W. (2017). Sulforaphane from broccoli reduces symptoms of autism: A follow-up case series from a randomized double-blind study. Global Advances in Health & Medicine. https://doi.org/10.1177/2164957X17735826CrossRef

Maenner, M., Shaw, K., & Bakian, A. (2021). Prevalence and characteristics of autism spectrum disorder among children aged 8 years—Autism and developmental disabilities monitoring network 11 sites United States, 2018. MMWR Surveillance Summaries, 70(11), 1–6.CrossRefPubMedCentral

McCracken, J. T., McGough, J., Shah, B., Cronin, P., Hong, D., Aman, M. G., Arnold, L. E., Lindsay, R., Nash, P., Hollway, J., McDougle, C. J., Posey, D., Swiezy, N., Kohn, A., Scahill, L., Martin, A., Koenig, K., Volkmar, F., Carroll, D., Lancor, A., Tierney, E., Ghuman, J., Gonzalez, N. M., Grados, M., Vitiello, B., Ritz, L., Davies, M., Robinson, J., McMahon, D., & Research Units on Pediatric Psychopharmacology Autism Network. (2002). Risperidone in children with autism and serious behavioral problems. New England Journal of Medicine, 347, 314–321. https://doi.org/10.1056/NEJMoa013171CrossRefPubMed

Momtazmanesh, S., Amirimoghaddam-Yazdi, Z., Moghaddam, H. S., Mohammadi, M. R., & Akhondzadeh, S. (2020). Sulforaphane as an adjunctive treatment for irritability in children with autism spectrum disorder: A randomized, double-blind, placebo-controlled clinical trial. Psychiatry and Clinical Neurosciences, 74, 398–405. https://doi.org/10.1111/pcn.13016CrossRefPubMed

Myzak, M. C., Tong, P., Dashwood, W. M., Dashwood, R. H., & Ho, E. (2007). Sulforaphane retards the growth of human PC-3 xenografts and inhibits HDAC activity in human subjects. Experimental Biology & Medicine, 232, 227–234.

OSU Rupp. (2005). OSU Autism Rating Scale—DSM-IV (OARS-4). OSU Research Unit on Pediatric Psychopharmacology.

Perrin, J. M., Coury, D. L., Hyman, S. L., Cole, L., Reynolds, A. M., & Clemons, T. (2012). Complementary and alternative medicine use in a large pediatric autism sample. Pediatrics, 130(Suppl 2), S77-82. https://doi.org/10.1542/peds.2012-0900ECrossRefPubMed

Sedlak, T. W., Nucifora, L. G., Koga, M., Shaffer, L. S., Higgs, C., Tanaka, T., Wang, A. M., Coughlin, J. M., Barker, P. B., Fahey, J. W., & Sawa, A. (2017). Sulforaphane augments glutathione and influences brain metabolites in human subjects: A clinical pilot study. Molecular Neuropsychiatry, 3, 214–222. https://doi.org/10.1159/000487639CrossRef

Selya, A. S., Rose, J. S., Dierker, L. C., Hedeker, D., & Mermelstein, R. J. (2012). A Practical guide to calculating Cohen’s f(2), a measure of local effect size, from PROC MIXED. Frontiers in Psychology, 3, 111. https://doi.org/10.3389/fpsyg.2012.00111CrossRefPubMedPubMedCentral

Singh, K., Connors, S. L., Macklin, E. A., Smith, K. D., Fahey, J. W., Talalay, P., & Zimmerman, A. W. (2014). Sulforaphane treatment of autism spectrum disorder (ASD). Proceedings of the National Academy of Sciences of the United States of America, 111, 15550–15555. https://doi.org/10.1073/pnas.1416940111CrossRefPubMedPubMedCentral

Tortorella, S. M., Royce, S. G., Licciardi, P. V., & Karagiannis, T. C. (2015). Dietary sulforaphane in cancer chemoprevention: The role of epigenetic regulation and HDAC inhibition. Antioxidants & Redox Signaling, 22, 1382–1424. https://doi.org/10.1089/ars.2014.6097CrossRef

Volkmar, F. R., Cicchetti, D. V., Dykens, E., Sparrow, S. S., Leckman, J. F., & Cohen, D. J. (1988). An evaluation of the autism behavior checklist. Journal of Autism and Developmental Disorders, 18, 81–97. https://doi.org/10.1007/bf02211820CrossRefPubMed

Walton, K. M., & Ingersoll, B. R. (2013). Improving social skills in adolescents and adults with autism and severe to profound intellectual disability: A review of the literature. Journal of Autism and Developmental Disorders, 43, 594–615. https://doi.org/10.1007/s10803-012-1601-1CrossRefPubMed

Wang, F., Lu, L., Wang, S. B., Zhang, L., Ng, C. H., Ungvari, G. S., Cao, X. L., Lu, J. P., Hou, C. L., Jia, F. J., & Xiang, Y. T. (2018). The prevalence of autism spectrum disorders in China: A comprehensive meta-analysis. Molecular Autism, 14, 717–725.

Wechsler, D. (2003). The Wechsler intelligence scale for children—fourth edition. Pearson.

Yagishita, Y., Fahey, J. W., Dinkova-Kostova, A. T., & Kensler, T. W. (2019). Broccoli or sulforaphane: Is it the source or dose that matters? Molecules. https://doi.org/10.3390/molecules24193593CrossRefPubMedPubMedCentral

Zimmerman, A. W., Singh, K., Connors, S. L., Liu, H., Panjwani, A. A., Lee, L. C., Diggins, E., Foley, A., Melnyk, S., Singh, I. N., James, S. J., Frye, R. E., & Fahey, J. W. (2021). Randomized controlled trial of sulforaphane and metabolite discovery in children with autism spectrum disorder. Molecular Autism, 12, 38. https://doi.org/10.1186/s13229-021-00447-5CrossRefPubMedPubMedCentral

Titel: Efficacy of Sulforaphane in Treatment of Children with Autism Spectrum Disorder: A Randomized Double-Blind Placebo-Controlled Multi-center Trial
Auteurs: Jianjun Ou
Robert C. Smith
Russell H. Tobe
Jingjing Lin
Jen Arriaza
Jed W. Fahey
Ruiting Liu
Ying Zeng
Yanan Liu
Lian Huang
Yidong Shen
Yamin Li
Daomeng Cheng
Brian Cornblatt
John M. Davis
Jingping Zhao
Renrong Wu
Hua Jin
Publicatiedatum: 24-11-2022
Uitgeverij: Springer US
Gepubliceerd in: Journal of Autism and Developmental Disorders / Uitgave 2/2024
Print ISSN: 0162-3257
Elektronisch ISSN: 1573-3432
DOI: https://doi.org/10.1007/s10803-022-05784-9

Bohn Stafleu van Loghum

Deel dit onderdeel of sectie (kopieer de link)

Abstract

Log in om toegang te krijgen

Andere artikelen Uitgave 2/2024

Social Validity of Pivotal Response Treatment for Young Autistic Children: Perspectives of Autistic Adults

Parental Perspectives: How Sensory Sensitivities Impact the Transition to Adulthood in Adolescents and Young Adults with Autism Spectrum Disorder

Supporting Caregivers Remotely During a Pandemic: Comparison of WHO Caregiver Skills Training Delivered Online Versus in Person in Public Health Settings in Italy

Heightened Anxiety and Depression Among Autistic Adolescents with ADHD: Findings From the National Survey of Children’s Health 2016–2019

Single-locus and Haplotype Associations of GRIN2B Gene with Autism Spectrum Disorders and the Demographic and Clinical Characteristics of Patients in Guilan, Iran

Brief Report: Assessment of a Caregiver-Implemented Intervention for Improving Social Communication Skills in Toddlers and Young Children with Autism